Natixis Advisors
SRPT icon

Natixis Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Natixis Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,137
Closed -$1.92M – 1639
2024
Q2 		$1.92M Buy
+12,137
New +$1.56M ﹤0.01% 1058
2023
Q4 		– Sell
-26,026
Closed -$3.15M – 1566
2023
Q3 		$3.15M Buy
26,026
+160
+0.6% +$18.1K 0.01% 843
2023
Q2 		$2.96M Sell
25,866
-1,119
-4% -$144K 0.01% 861
2023
Q1 		$3.72M Buy
26,985
+131
+0.5% +$17K 0.01% 777
2022
Q4 		$3.48M Buy
26,854
+506
+2% +$58.6K 0.01% 780
2022
Q3 		$2.91M Buy
26,348
+1,416
+6% +$143K 0.01% 782
2022
Q2 		$1.87M Sell
24,932
-2,218
-8% -$163K 0.01% 930
2022
Q1 		$2.12M Buy
27,150
+1,656
+6% +$127K 0.01% 946
2021
Q4 		$2.3M Buy
25,494
+724
+3% +$61.9K 0.01% 907
2021
Q3 		$2.29M Buy
24,770
+634
+3% +$48.8K 0.01% 885
2021
Q2 		$1.88M Buy
24,136
+4,527
+23% +$343K 0.01% 927
2021
Q1 		$1.46M Sell
19,609
-832
-4% -$76.8K 0.01% 962
2020
Q4 		$3.48M Buy
20,441
+8,231
+67% +$1.22M 0.02% 682
2020
Q3 		$1.72M Buy
12,210
+461
+4% +$70.1K 0.01% 835
2020
Q2 		$1.88M Sell
11,749
-1,486
-11% -$202K 0.01% 824
2020
Q1 		$1.29M Sell
13,235
-352
-3% -$40.2K 0.01% 840
2019
Q4 		$1.75M Buy
+13,587
New +$1.37M 0.01% 837

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Natixis Advisors's SRPT Position: Q3 2024 in Review

Natixis Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 12,137 shares — an estimated $1.92M sold.

Natixis Advisors first reported a position in SRPT in Q4 2019 and held it in 17 quarters. The position peaked at $3.72M in Q1 2023. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Natixis Advisors reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Natixis Advisors sold 12,137 Sarepta Therapeutics shares in Q3 2024, an estimated $1.92M.
  • Natixis Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 17 quarters.
  • Natixis Advisors's Sarepta Therapeutics position peaked at $3.72M in Q1 2023.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Natixis Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.